Chronic granulomatous disease (CGD) is an uncommon primary immunodeficiency affecting the innate immune system and is characterized by recurrent and severe infections.
Epidemiology
Incidence – 1/200,000 births
Age – early presentation with mean age of diagnosis between 0 and 8 years
Sex – males predominate (85%)
Inheritance
Both X-linked (65-70%) and autosomal recessive forms
Involves mutations in the 13 exons encoding the CYBB gene
Pathophysiology
Neutrophils are the first line of defense against bacterial and fungal infections
Neutrophils migrate to the site of infection where phagocytosis then occurs
Neutrophil granules fuse to the phagosome and microbicidal reactive oxygen products are generated
CGD involves defective microbicidal oxidant production secondary to a defect in the neutrophil respiratory burst
Defects result in decreased production of superoxide, hydrogen peroxide, hydroxyl radical and hypochlorite ion within neutrophil and macrophages
Most common infections are bacterial infections produced by catalase-positive microorganisms and fungal organisms
Disorder makes patients susceptible to infectious organisms that may be nonpathogenic in normal host
Molecular defects associated with disease result in malfunction of one of the phagocyte NADPH oxidase components
Clinical Presentation
Clinical manifestations usually appear very early in childhood, but may not present until later in life, especially with autosomal recessive or variant form of sex-linked CGD
Use along with other clinical findings to diagnose chronic granulomatous disease (CGD)
Characterize autosomal recessive CGD and X-linked carrier status
Test results alone not diagnostic
Test is time sensitive
For abnormal results, ARUP encourages consultation with medical director of Immunology Laboratory
Guidelines
Practice parameter for the diagnosis and management of primary immunodeficiency. American Academy of Allergy, Asthma and Immunology - Medical Specialty Society. American College of Allergy, Asthma and Immunology - Medical Specialty Society. Joint Council of Allergy, Asthma and Immunology - Medical Specialty Society. 1995 Aug 31 (revised 2005 May). 63 pages. NGC:004445
(Link to NGC)
General References
Assari T.Chronic Granulomatous Disease; fundamental stages in our understanding of CGD.Med Immunol. 2006;5:4-. (Link to PubMed)
Hernandez M, Bastian JF.Immunodeficiency in childhood.Curr Allergy Asthma Rep. 2006;6(6):468-474. (Link to PubMed)
Johnston RB Jr.Clinical aspects of chronic granulomatous disease.Curr Opin Hematol. 2001;8(1):17-22. (Link to PubMed)
Jurkowska M, Bernatowska E, Bal J.Genetic and biochemical background of chronic granulomatous disease.Arch Immunol Ther Exp (Warsz ). 2004;52(2):113-120. (Link to PubMed)
Rosenzweig SD.Inflammatory Manifestations in Chronic Granulomatous Disease (CGD).J Clin Immunol. 2008;-. (Link to PubMed)
Soler-Palacin P, Margareto C, Llobet P, Asensio O, Hernandez M, Caragol I, Espanol T.Chronic granulomatous disease in pediatric patients: 25 years of experience.Allergol Immunopathol (Madr ). 2007;35(3):83-89. (Link to PubMed)
Reviewed by
Hill, Harry R., M.D. Group Medical Director, Laboratory of Immunology, ARUP Laboratories, and Executive Director of the ARUP Institute for Clinical and Experimental Pathology; Professor and Division Head, Clinical Pathology, University of Utah
Comprehensive Review: July 2008
Last Update: July 2008